These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 24998941)

  • 21. In vitro and in vivo evaluation of in situ gelling systems for sustained topical ophthalmic delivery: state of the art and beyond.
    Destruel PL; Zeng N; Maury M; Mignet N; Boudy V
    Drug Discov Today; 2017 Apr; 22(4):638-651. PubMed ID: 28017837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent patents on ophthalmic nanoformulations and therapeutic implications.
    Ako-Adounvo AM; Nagarwal RC; Oliveira L; Boddu SH; Wang XS; Dey S; Karla PK
    Recent Pat Drug Deliv Formul; 2014; 8(3):193-201. PubMed ID: 25262835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances.
    Wang R; Gao Y; Liu A; Zhai G
    J Drug Target; 2021 Aug; 29(7):687-702. PubMed ID: 33474998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent developments in ocular drug delivery.
    Chen H
    J Drug Target; 2015; 23(7-8):597-604. PubMed ID: 26453157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymer-based carriers for ophthalmic drug delivery.
    Imperiale JC; Acosta GB; Sosnik A
    J Control Release; 2018 Sep; 285():106-141. PubMed ID: 29964135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in ocular drug delivery.
    Achouri D; Alhanout K; Piccerelle P; Andrieu V
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1599-617. PubMed ID: 23153114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ocular delivery systems for topical application of anti-infective agents.
    Duxfield L; Sultana R; Wang R; Englebretsen V; Deo S; Rupenthal ID; Al-Kassas R
    Drug Dev Ind Pharm; 2016 Jan; 42(1):1-11. PubMed ID: 26325119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent Advancemnts in Biodegradable Ocular Implants.
    Mittal S; Miranda O
    Curr Drug Deliv; 2018 Feb; 15(2):144-154. PubMed ID: 28482784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How can nanoparticles be used to overcome the challenges of glaucoma treatment?
    Venkatraman S; Wong T
    Nanomedicine (Lond); 2014 Jul; 9(9):1281-3. PubMed ID: 25204817
    [No Abstract]   [Full Text] [Related]  

  • 30. Ocular Drug Delivery: Role of Degradable Polymeric Nanocarriers for Ophthalmic Application.
    Tsai CH; Wang PY; Lin IC; Huang H; Liu GS; Tseng CL
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30235809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advance of the application of nano-controlled release system in ophthalmic drug delivery.
    Wang X; Wang S; Zhang Y
    Drug Deliv; 2016 Oct; 23(8):2897-2901. PubMed ID: 26635087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug Delivery for Ocular Allergy: Current Formulation Design Strategies and Future Perspectives.
    Regu VR; Swain RP; Subudhi BB
    Curr Pharm Des; 2023; 29(33):2626-2639. PubMed ID: 37936454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of thermosensitive in situ gels and drug-resin complex for ocular drug delivery: In vitro drug release and in vivo tissue distribution.
    Wei Y; Li C; Zhu Q; Zhang X; Guan J; Mao S
    Int J Pharm; 2020 Mar; 578():119184. PubMed ID: 32112932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fundamentals, challenges, and nanomedicine-based solutions for ocular diseases.
    Srinivasarao DA; Lohiya G; Katti DS
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jul; 11(4):e1548. PubMed ID: 30506871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses.
    Gause S; Hsu KH; Shafor C; Dixon P; Powell KC; Chauhan A
    Adv Colloid Interface Sci; 2016 Jul; 233():139-154. PubMed ID: 26318359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravitreal, Subretinal, and Suprachoroidal Injections: Evolution of Microneedles for Drug Delivery.
    Hartman RR; Kompella UB
    J Ocul Pharmacol Ther; 2018; 34(1-2):141-153. PubMed ID: 29206556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In Situ Gelling Ophthalmic Drug Delivery System: An Overview and Its Applications.
    Sheshala R; Kok YY; Ng JM; Thakur RR; Dua K
    Recent Pat Drug Deliv Formul; 2015; 9(3):237-48. PubMed ID: 26205681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stimuli-Responsive Polymeric Systems for Controlled Protein and Peptide Delivery: Future Implications for Ocular Delivery.
    Mahlumba P; Choonara YE; Kumar P; du Toit LC; Pillay V
    Molecules; 2016 Jul; 21(8):. PubMed ID: 27483234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Controlled release of vitamin A palmitate from crosslinked cyclodextrin organic framework for dry eye disease therapy.
    Ye X; Li F; Li M; Zhang G; Wang W; Wang Z; Zhang H; Dong L; Lin X; Wu L; Peng C; Wang L; Chen W; Zhang J
    Int J Pharm; 2024 Jun; 659():124279. PubMed ID: 38806096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prolonged Release Niosomes For Ocular Delivery of Loteprednol: Ocular Distribution Assessment on Dry Eye Disease Induced Rabbit Model.
    Ozdemir S; Uner B
    AAPS PharmSciTech; 2024 May; 25(5):119. PubMed ID: 38816667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.